PUBLIC COMPANY
saveGILEAD
USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Gilead CAR-T on partial clinical hold; Agios' PDUFA date pushed backPlus news about Acumen, Bristol Myers Squibb, Regeneron, Aer Therapeutics and Hemay Pharmaceutical. Gilead pauses CAR-T after ICANS: After several cases of the neurological condition known as ICANS…endpoints · 1d ago
- Immutep, Molecular cut workforcesFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- AstraZeneca cuts early-phase prostate cancer pipelineAstraZeneca has punted a pair of early-phase prostate cancer programs as part of its quarterly pipeline clear out.fiercebiotech · 2d ago
- Gilead reveals partial clinical hold on 2 CAR-T cell therapy trialsGilead Sciences announced on its third-quarter earnings call Oct. 29 that the company has placed a partial clinical hold on two studies for the CAR-T cell therapy KITE-753 in diffuse large B-cell l…fiercebiotech · 2d ago
- STAT+: Vertex kidney disease drug scrutinized for infection riskAhead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk.stat · 2d ago
- Biopharma cuts at manufacturing plants expected to affect 4,000+As companies invest billions of dollars to reshore manufacturing, 10 biotech and pharma businesses are reportedly trimming staff at manufacturing locations in 2026 or the coming years, with BioNTec…biospace · 3d ago
- Astellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woesAstellas has struck a deal for Audax Biosciences’ IL-12 program, committing up to $285 million in upfront and option fees to secure a chance to license the preclinical immuno-oncology program.fiercebiotech · 4d ago
- 5 new drug launches that defied industry expectationsA clearly superior clinical profile, reasonable pricing and easy access has helped a handful of recently approved therapies achieve impressive launches.biospace · 4d ago
- Parkinson’s-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOsParkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are each hoping to raise around $134 million from their respective IPOs.fiercebiotech · 4d ago
- STAT+: House lawmaker probes PBMs for ‘punitive’ audits of independent pharmaciesA House lawmaker is investigating whether the three largest PMS targeted independent pharmacies withretaliatory audits.stat · 5d ago
comments(0)
5-min edit window · permanent after that